Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells:: Up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein

被引:140
作者
Rölle, A
Mousavi-Jazi, M
Eriksson, M
Odeberg, J
Söderberg-Nauclér, C
Cosman, D
Kärre, K
Cerboni, C
机构
[1] Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden
[2] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden
[3] Swedish Inst Infect Dis Control, Stockholm, Sweden
[4] Amgen Inc, Dept Mol Biol, Seattle, WA 98101 USA
关键词
D O I
10.4049/jimmunol.171.2.902
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human CMV (HCMV) interferes with NK cell functions at various levels. The HCMV glycoprotein UL16 binds some of the ligands recognized by the NK-activating receptor NKG2D, namely UL16-binding proteins (ULBP) 1 and 2 and MHC class I-related chain B, possibly representing another mechanism of viral immune escape. This study addressed the expression and function of these proteins in infected cells. HCMV induced the expression of all three ULBPs, which were predominantly localized in the endoplasmic reticulum of infected fibroblasts together with UL16. However, while at a lower viral dose ULBP1 and 2 surface expression was completely inhibited compared to ULBP3, at a higher viral dose cell surface expression of ULBP1 and ULBP2 was delayed. The induction of ULBPs correlated with an increased dependency on NKG2D for recognition; however, the overall NK sensitivity did not change (suggesting that additional viral mechanisms interfere with NKG2D-independent pathways for recognition). Infection with a UL16 deletion mutant virus resulted in a different pattern compared to the wild type: all three ULBP molecules were induced with similar kinetics at the cell surface, accompanied by a pronounced, entirely NKG2D-dependent increase in NK sensitivity. Together our findings show that upon infection with HCMV, the host cell responds by expression of ULBPs and increased susceptibility to the NKG2D-mediated component of NK cell recognition, but UL16 limits these effects by interfering with the surface expression of ULBP1 and ULBP2.
引用
收藏
页码:902 / 908
页数:7
相关论文
共 36 条
[1]   Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors [J].
Arase, H ;
Mocarski, ES ;
Campbell, AE ;
Hill, AB ;
Lanier, LL .
SCIENCE, 2002, 296 (5571) :1323-1326
[2]   Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA [J].
Bauer, Stefan ;
Groh, Veronika ;
Wu, Jun ;
Steinle, Alexander ;
Phillips, Joseph H. ;
Lanier, Lewis L. ;
Spies, Thomas .
JOURNAL OF IMMUNOLOGY, 2018, 200 (07) :2231-2233
[3]   Natural killer cells in antiviral defense: Function and regulation by innate cytokines [J].
Biron, CA ;
Nguyen, KB ;
Pien, GC ;
Cousens, LP ;
Salazar-Mather, TP .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :189-220
[4]  
Braud VM, 2002, CURR TOP MICROBIOL, V269, P117
[5]   Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts [J].
Cerboni, C ;
Mousavi-Jazi, M ;
Linde, A ;
Söderström, K ;
Brytting, M ;
Wahren, B ;
Kärre, K ;
Carbone, E .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4775-4782
[6]   A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules [J].
Cosman, D ;
Fanger, N ;
Borges, L ;
Kubin, M ;
Chin, W ;
Peterson, L ;
Hsu, ML .
IMMUNITY, 1997, 7 (02) :273-282
[7]   ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor [J].
Cosman, D ;
Müllberg, J ;
Sutherland, CL ;
Chin, W ;
Armitage, R ;
Fanslow, W ;
Kubin, M ;
Chalupny, NJ .
IMMUNITY, 2001, 14 (02) :123-133
[8]   A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity [J].
Diefenbach, A ;
Hsia, JK ;
Hsiung, MYB ;
Raulet, DH .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (02) :381-391
[9]   Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity [J].
Dunn, C ;
Chalupny, NJ ;
Sutherland, CL ;
Dosch, S ;
Sivakumar, PV ;
Johnson, DC ;
Cosman, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (11) :1427-1439
[10]  
Fletcher JM, 1998, J IMMUNOL, V161, P2365